Efficacy and Safety of Eco-friendly Inhalers: Focus on Combination Ipratropium Bromide and Albuterol in Chronic Obstructive Pulmonary Disease

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2013 May 10

PMID 23658481

Citations 3

Authors

Ralph J Panos

Affiliations

Soon will be listed here.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and its treatment is critical to improve quality of life, reduce symptoms, and diminish the frequency of COPD exacerbations. Due to the harmful environmental effects of pressurized metered-dose inhalers (pMDIs) containing chlorofluorocarbons (CFCs), newer systems for delivering respiratory medications have been developed.

Methods: A search of the literature in the PubMed database was undertaken using the keywords "COPD," "albuterol," "ipratropium bromide," and "Respimat® Soft Mist Inhaler™"; pertinent references within the identified citations were included. The environmental effect of CFC-pMDIs, the invention of the Respimat® Soft Mist Inhaler™ (SMI) (Boehringer Ingelheim, Ingelheim, Germany), and its use to deliver the combination of albuterol and ipratropium bromide for the treatment of COPD were reviewed.

Results: The adverse environmental effects of CFC-pMDIs stimulated the invention of novel delivery systems including the Respimat SMI. This review presents its development, internal mechanism, and use to deliver the combination of albuterol and ipratropium bromide.

Conclusion: CFC-pMDIs contributed to the depletion of the ozone layer and the surge in disorders caused by harmful ultraviolet B radiation. The banning of CFCs spurred the development of novel delivery systems for respiratory medications. The Respimat SMI is an innovative device that produces a vapor of inhalable droplets with reduced velocity and prolonged aerosol duration that enhance deposition within the lower airway and is associated with improved patient satisfaction. Clinical trials have demonstrated that the Respimat SMI can achieve effects equivalent to pMDIs but with lower medication doses. The long-term safety and efficacy remain to be determined. The Respimat SMI delivery device is a novel, efficient, and well-received system for the delivery of aerosolized albuterol and ipratropium bromide to patients with COPD; however, the presence of longer-acting, less frequently dosed respiratory medications provide patients and providers with other therapeutic options.

Citing Articles

Pharmacokinetics and Tissue Distribution of Nasal Spray of a Novel Muscarinic Receptor Blocker, 101BHG-D01, in Dogs and Rats.

Wei H, Wu L, Jia Y, Shen J, Li Y, Sun P Curr Drug Metab. 2022; 23(13):1080-1088.

PMID: 36464876 PMC: 10186379. DOI: 10.2174/1389200224666221201123254.

Effect of MDI Actuation Timing on Inhalation Dosimetry in a Human Respiratory Tract Model.

Talaat M, Si X, Xi J Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056118 PMC: 8777964. DOI: 10.3390/ph15010061.

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.

Donohue J, Wise R, Busse W, Garfinkel S, Zubek V, Ghafouri M BMC Pulm Med. 2016; 16(1):65.

PMID: 27130202 PMC: 4851785. DOI: 10.1186/s12890-016-0223-3.

References

Hodder R, Price D . Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009; 4:381-90. PMC: 2829861. DOI: 10.2147/copd.s3391. View

Zeidler M, Corren J . Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med. 2004; 3(1):35-44. DOI: 10.2165/00151829-200403010-00005. View

Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault J . Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med. 2000; 94(5):490-5. DOI: 10.1053/rmed.1999.0770. View

Fabbri L, Luppi F, Beghe B, Rabe K . Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31(1):204-12. DOI: 10.1183/09031936.00114307. View

Jenkins C, Beasley R . Tiotropium Respimat increases the risk of mortality. Thorax. 2012; 68(1):5-7. DOI: 10.1136/thoraxjnl-2012-202482. View

Harrison E . Change in the air. Banning CFC-driven inhalers could levy a toll on asthma sufferers. Sci Am. 2008; 299(2):20, 22. View

Anthonisen N, Connett J, Enright P, Manfreda J . Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002; 166(3):333-9. DOI: 10.1164/rccm.2110093. View

Ram F, Brocklebank D, Muers M, Wright J, Jones P . Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002; (1):CD002170. PMC: 8436731. DOI: 10.1002/14651858.CD002170. View

Rogers H, Weinstock M, Harris A, Hinckley M, Feldman S, Fleischer A . Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146(3):283-7. DOI: 10.1001/archdermatol.2010.19. View

10.

van Noord J, Smeets J, Creemers J, Greefhorst L, Dewberry H, CORNELISSEN P . Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration. 2000; 67(6):672-8. DOI: 10.1159/000056298. View

11.

Macie C, Wooldrage K, Manfreda J, Anthonisen N . Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008; 3(1):163-9. PMC: 2528211. DOI: 10.2147/copd.s1516. View

12.

Barnes P, Celli B . Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5):1165-85. DOI: 10.1183/09031936.00128008. View

13.

Decramer M, Rennard S, Troosters T, Mapel D, Giardino N, Mannino D . COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD. 2008; 5(4):235-56. DOI: 10.1080/15412550802237531. View

14.

Newman S, Brown J, Steed K, Reader S, Kladders H . Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998; 113(4):957-63. DOI: 10.1378/chest.113.4.957. View

15.

Rowland F . Stratospheric ozone depletion. Philos Trans R Soc Lond B Biol Sci. 2006; 361(1469):769-90. PMC: 1609402. DOI: 10.1098/rstb.2005.1783. View

16.

Ogale S, Lee T, Au D, Boudreau D, Sullivan S . Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2009; 137(1):13-9. DOI: 10.1378/chest.08-2367. View

17.

Dalby R, Spallek M, Voshaar T . A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004; 283(1-2):1-9. DOI: 10.1016/j.ijpharm.2004.06.018. View

18.

Reed K, Brewer J, Lohse C, Bringe K, Pruitt C, Gibson L . Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012; 87(4):328-34. PMC: 3538462. DOI: 10.1016/j.mayocp.2012.01.010. View

19.

Velders G, Andersen S, Daniel J, Fahey D, McFarland M . The importance of the Montreal Protocol in protecting climate. Proc Natl Acad Sci U S A. 2007; 104(12):4814-9. PMC: 1817831. DOI: 10.1073/pnas.0610328104. View

20.

Newman S, Steed K, Reader S, Hooper G, Zierenberg B . Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996; 85(9):960-4. DOI: 10.1021/js950522q. View